Drugs / OL-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06644118 | Oct 2024 → Oct 2027 expected | plasma cell myeloma | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OL-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06644118 ↗ |
| Modality | Cell therapy | “a chimeric antigen receptor T cell (CAR-T) therapy” NCT06644118 ↗ |
| Route | Intravenous | “OL-101 infusion will be administered to patients via IV infusion at the assigned dose.” NCT06644118 ↗ |